| Bid | 21 |
| Market Cap | 1.07B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.44 |
| PE Ratio (ttm) | 49.14 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 22.4 |
| Volume | 549,609 |
| Avg. Volume (20D) | 627,873 |
| Open | 22.66 |
| Previous Close | 22.48 |
| Day's Range | 21.13 - 22.66 |
| 52-Week Range | 21.13 - 52.68 |
| Beta | undefined |
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone c...
Analyst Forecast
According to 7 analyst ratings, the average rating for STAA stock is "Hold." The 12-month stock price forecast is $42, which is an increase of 94.26% from the latest price.
Next Earnings Release
Analysts project revenue of $80.35M, reflecting a 5.35% YoY growth and earnings per share of 0.08, making a -50.00% decrease YoY.
2 months ago · businesswire.com
CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 ResultsLAKE FOREST, Calif.--(BUSINESS WIRE)--The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2%...
2 months ago · businesswire.com
STAAR Surgical to Report Third Quarter Results on October 30, 2024LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, ast...